Aqua Medical Achieves Major Milestone in Type 2 Diabetes Treatment with Innovative Endoscopic Procedure

Aqua Medical's Revolutionary Approach to Type 2 Diabetes Treatment

In a groundbreaking development for diabetes management, Aqua Medical, Inc. has announced the successful treatment of its first patient in the United States utilizing its pioneering Endoscopic Metabolic Restoration technology. This milestone was achieved at UNC Health in Chapel Hill, North Carolina, which is one of only four distinguished U.S. academic medical centers participating in this multicenter FDA-authorized clinical trial.

The procedure, known as Proximal Intestinal Mucosal Ablation (PIMA), is facilitated through Aqua Medical's proprietary radiofrequency vapor ablation (RFVA) platform, which allows for a minimally invasive treatment option. This innovative approach targets a specific area of the proximal small intestine, addressing the metabolic disruptions commonly associated with type 2 diabetes. By using a standard endoscope, the procedure can be performed without the need for fluoroscopy, making it more accessible and patient-friendly.

Dr. Nicholas Shaheen, a highly regarded gastroenterologist and National Principal Investigator of the study, led the treatment, highlighting the clinical significance of this procedure. Partnering with Dr. John B. Buse, a leading authority in endocrinology, the study aims to investigate the safety and efficacy of the PIMA procedure for patients whose type 2 diabetes remains poorly controlled despite standard treatment options.

The significance of Aqua Medical's approach cannot be overstated. With over 66 patients treated outside the United States, the positive safety and clinical data collected has set the groundwork for this FDA-authorized U.S. investigational study. Initial findings have shown that patients experience significant improvements, including complete insulin elimination—a promising indicator of the procedure's potential impact.

Moreover, this endoscopic solution offers a scalable and effective alternative to traditional diabetes management strategies, bridging the gap between conventional pharmacological treatments and more invasive bariatric surgeries. "This procedure could transform how we approach metabolic diseases, making advanced therapies more accessible to a wider range of patients," remarked Dr. Raj Nihalani, Chief Medical Officer of Aqua Medical.

As patient enrollment continues at several study sites across the United States, Aqua Medical anticipates that the outcomes of the IDE clinical trial will pave the way for a new standard in diabetes care. This innovative technology not only aims to enhance the quality of care but also seeks to significantly reduce dependence on lifelong medication.

In conclusion, Aqua Medical's advances highlight the importance of innovation in tackling chronic health issues such as type 2 diabetes. As the first patient has been treated under the study, it marks a critical step forward in the fight against this pervasive condition. With committed clinical oversight from respected leaders in the field and a robust scientific framework backing their technology, Aqua Medical is positioned at the forefront of transforming diabetes management for millions worldwide.

This represents an exhilarating phase for Aqua Medical, unveiling a potential shift in the treatment landscape for type 2 diabetes as they work towards expanding this groundbreaking procedure to benefit patients everywhere.